Lars Björnebo

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: EUROPEAN UROLOGY FOCUS. 2025;:S2405-4569(25)00175-0
Prostate-specific Antigen Density as a Selection Tool Before Magnetic Resonance Imaging in Prostate Cancer Screening: An Analysis from the STHLM3MRI Randomized Clinical Trial.
Björnebo L; Discacciati A; Abbadi A; Falagario UG; Engel JC; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Lantz A; Nordström T
Article: ECLINICALMEDICINE. 2025;82:103191
Evaluating the performance of existing tools to predict clinically significant prostate cancer in men with indeterminate lesions on biparametric MRI and development of a novel multiplex model: a prospective cohort study
Abbadi A; Eklund M; Lantz A; Discacciati A; Bjornebo L; Palsdottir T; Engel JC; Jaderling F; Falagario U; Gronberg H; Nordstrom T
Journal article: ECLINICALMEDICINE. 2025;82:103191
Evaluating the performance of existing tools to predict clinically significant prostate cancer in men with indeterminate lesions on biparametric MRI and development of a novel multiplex model: a prospective cohort study.
Abbadi A; Eklund M; Lantz A; Discacciati A; Björnebo L; Palsdottir T; Chandra Engel J; Jäderling F; Falagario U; Grönberg H; Nordström T
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2024;116(9):1459-1465
Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists
Bjornebo L; Razdan S; Discacciati A; Palsdottir T; Aly M; Nordstrom T; Eklund M; Lundon D; Gronberg H; Tewari A; Wiklund P; Kyprianou N; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e1213
PD57-12 PSA RESPONSE AFTER RADIOTHERAPY. IS THERE A DEFINITION OF PSA PERSISTENCE AFTER RT?
Falagario UG; Pellegrino F; Abbadi A; Björnebo L; Valdman A; Carrieri GG; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e623
PD29-12 THE IMPACT OF THE TIME ELAPSED BETWEEN PRIMARY TREATMENT AND BCR ON CANCER SPECIFIC MORTALITY IN PATIENTS WHO EXPERIENCED BCR AFTER PRIMARY TREATMENT
Pellegrino F; Falagario UG; Abbadi A; Björnebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
Article: EUROPEAN UROLOGY OPEN SCIENCE. 2024;62:61-67
Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer
Arvendell M; Bjornebo L; Eklund M; Falagario UG; Engel JC; Akre O; Gronberg H; Nordstrom T; Lantz A
Article: JAMA NETWORK OPEN. 2024;7(4):e247131
Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial
Bjornebo L; Discacciati A; Falagario U; Vigneswaran HT; Jaderling F; Gronberg H; Eklund M; Nordstrom T; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1598
Can we reduce unnecessary prostate biopsies in patients with PI-RADS 3 lesions? Role of PSA density and the Stockholm 3 test
Abbadi A; Eklund M; Lantz A; Discacciati A; Engel CJ; Bjornebo L; Falagario UG; Gronberg H; Nordstrom T
Journal article: EUROPEAN UROLOGY. 2024;85:s348
Pre-diagnostic prostate-specific antigen testing and clinical characteristics in men deceased from prostate cancer
Arvendell M; Bjornebo L; Eklund M; Falagario GU; Akre O; Gronberg H; Nordstrom T; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1402-s1403
PSA response after radiotherapy. Is there a definition of PSA persistence after RT?
Falagario UG; Pellegrino F; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1534-s1535
The impact of the time elapsed between primary treatment and BCR on cancer specific mortality in patients who experienced BCR after primary treatment
Pellegrino F; Falagario UG; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Article: WORLD JOURNAL OF UROLOGY. 2023;41(11):2967-2974
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
Falagario UG; Lantz A; Jambor I; Busetto GM; Bettocchi C; Finati M; Ricapito A; Luzzago S; Ferro M; Musi G; Totaro A; Racioppi M; Carbonara U; Checcucci E; Manfredi M; D'Aietti D; Porcaro AB; Nordstrom T; Bjornebo L; Oderda M; Soria F; Taimen P; Aronen HJ; Perez IM; Ettala O; Marchioni M; Simone G; Ferriero M; Brassetti A; Napolitano L; Carmignani L; Signorini C; Conti A; Ludovico G; Scarcia M; Trombetta C; Claps F; Traunero F; Montanari E; Boeri L; Maggi M; Del Giudice F; Bove P; Forte V; Ficarra V; Rossanese M; Mucciardi G; Pagliarulo V; Tafuri A; Mirone V; Schips L; Antonelli A; Gontero P; Cormio L; Sciarra A; Porpiglia F; Bassi P; Ditonno P; Bostrom PJ; Messina E; Panebianco V; De Cobelli O; Carrieri G
Article: JAMA NETWORK OPEN. 2023;6(9):e2332900
Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy
Falagario UG; Abbadi A; Remmers S; Bjornebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e419
PD15-04 PREDICTION OF PROSTATE CANCER SPECIFIC MORTALITY IN MEN UNDERGOING RADIOTHERAPY WITH OR WITHOUT HORMONAL TREATMENT, RISK STRATIFICATION BASED ON CLINICAL CHARACTERISTICS AND PSA TREATMENT RESPONSE
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e214
MP17-06 VALIDATION OF EAU RISK GROUPS FOR BIOCHEMICAL RECURRENCE AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY FOR PREDICTION OF PROSTATE CANCER MORTALITY
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Journal article: EUROPEAN UROLOGY. 2023;83:s1613-s1614
Prediction of prostate cancer specific mortality in men undergoing radiotherapy with or without hormonal treatment, risk stratification based on clinical characteristics and PSA treatment response
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2023;83:s379-s380
A0266 Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Article: JAMA ONCOLOGY. 2022;8(7):1019-1026
Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e991
MP58-03 PROSTATE CANCER SCREENING - A NOVEL RISK PREDICTION TOOL WITH STANDARD BIOPSIES VS. PSA WITH MRI-TARGETED BIOPSIES
Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Journal article: INVESTIGATIVE UROLOGY. 2022;207(Supplement 5):e41
PD03-02 LONG-TERM EFFECTS OF 5Α-REDUCTASE INHIBITORS ON PROSTATE CANCER MORTALITY - A LARGE POPULATION-BASED PROSPECTIVE STUDY
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY. 2022;81:s561-s562
A0362 Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
Journal article: EUROPEAN UROLOGY. 2022;81:s554-s555
A0358 Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies
Björnebo L; Discacciati A; Eklund M; Grönberg H; Lantz A; Nordström T
Article: WORLD JOURNAL OF UROLOGY. 2021;39(6):1797-1804
Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer
Bjornebo L; Olsson H; Nordstrom T; Jaderling F; Gronberg H; Eklund M; Lantz A
Visa fler

Alla övriga publikationer

Doctoral thesis: 2024
Improving detection and reducing overtreatment of prostate cancer
Björnebo L
Thesis / dissertation: KAROLINSKA INSTITUTET. 2024
Improving detection and reducing overtreatment of prostate cancer
Björnebo L
Conference publication: EUROPEAN UROLOGY. 2023;83:S379-S380
Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Lantz A; Wiklund P
Letter: JAMA ONCOLOGY. 2022;8(12):1852
Association of 5a-Reductase Inhibitor Use With Prostate Cancer-Specific Mortality-Reply
Bjornebo L; Eklund M; Lantz A
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7844
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation
Sanguedolce F; Zanelli M; Palicelli A; Ascani S; Zizzo M; Cocco G; Bjornebo L; Lantz A; Landriscina M; Conteduca V; Falagario UG; Cormio L; Carrieri G
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022;23(14):7819
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression
Sanguedolce F; Zanelli M; Palicelli A; Ascani S; Zizzo M; Cocco G; Bjornebo L; Lantz A; Falagario UG; Cormio L; Carrieri G
Conference publication: EUROPEAN UROLOGY. 2022;81:S561-S562
Long-term effects of 5α-reductase inhibitors on prostate cancer mortality: A large population-based prospective study
Bjornebo L; Nordstrom T; Discacciati A; Palsdottir T; Aly M; Gronberg H; Eklund M; Lantz A
Conference publication: EUROPEAN UROLOGY. 2022;81:S554-S555
Prostate cancer screening: A novel risk prediction tool with standard biopsies vs. PSA with MRI-targeted biopsies
Bjornebo L; Discacciati A; Eklund M; Gronberg H; Lantz A; Nordstrom T
Review: CELL COMMUNICATION AND SIGNALING. 2021;19(1):78
Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease
Archer M; Dogra N; Dovey Z; Ganta T; Jang H-S; Khusid JA; Lantz A; Mihalopoulos M; Stockert JA; Zahalka A; Bjornebo L; Gaglani S; Noh MR; Kaplan SA; Mehrazin R; Badani KK; Wiklund P; Tsao K; Lundon DJ; Mohamed N; Lucien F; Padanilam B; Gupta M; Tewari AK; Kyprianou N

Anställningar

Anknuten till Forskning, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2025-2027
Doktorand, Medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2020-2024

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicinsk epidemiologi och biostatistik, Karolinska Institutet, 2024
Läkarexamen, Karolinska Institutet, 2022

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI